# A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

> **NCT04906876** · PHASE2 · WITHDRAWN · sponsor: **Brown University**

## Conditions studied

- Sarcoma
- Soft Tissue Sarcoma
- Metastatic Sarcoma
- Undifferentiated Pleomorphic Sarcoma
- Myxofibrosarcoma
- Leiomyosarcoma
- Liposarcoma
- Angiosarcoma
- Synovial Sarcoma
- Rhabdomyosarcoma
- Spindle Cell Sarcoma
- High Grade Sarcoma
- Bone Sarcoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** 9-ING-41

## Key facts

- **NCT ID:** NCT04906876
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09
- **Primary completion:** 2022-07
- **Final completion:** 2025-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** IND withdrawn
- **Last updated:** 2021-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04906876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04906876, "A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04906876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*